The Curative Effect Research Of Multicellular Immunotherapy On Ⅲ～Ⅳ Stages Of Digestive Tract Malignant Tumor

Objective:To study the curative effect of multicellular immunotherapy at the treatment of Ⅲ～Ⅳ stages of digestive tract malignant tumor. Methods:47 cases of Ⅲ～Ⅳ stages of digestive tract malignant tumor in our hospital from January 2014 to February 2015 were analyzed retrospectively. This therapy included DC, CIK, and CD3AK cell therapy. Collected peripheral blood to measure T cell subsets before and after the treatment respectively. Analyzed and compared patients’QOL scores, KPS scores, PS scores, tumor markers and the changes of T cell subgroups and recent effects before and after the treatment. Results:After 1 cycle of multicellular immunotherapy, peripheral blood T cell subsets before and after multicellular immunotherapy:In esophageal cancer, CD4+T/CD8+T higher after treatment than before treatment, the difference was statistically significant (P< 0.01), CD3+T, CD4+T, CD8+T changes before and after the treatment had no statistical significance (P> 0.05); In colorectal cancer, CD4+T, CD4 T/CD8+T higher after treatment than before treatment, the differences were statistically significant (P< 0.05), there were no statistically significant differences of CD3+T, CD8+T (P> 0.05); In patients with gastric cancer, CD3+T, CD4+T, CD4+T/CD8+T after treatment were higher, the differences were statistically significant (P< 0.01), and CD8+T lower than before the treatment (P< 0.01). The tumor markers’(CEA, CA72-4, CA19-9) differences in patients with esophageal cancer and colorectal cancer have no obvious change (P> 0.05); In patients with gastric cancer, CEA, CA72-4 decreased, compared with before the treatment and the differences were statistically significant (P< 0.05), CA19-9 was no statistically significant difference before and after treatment (P> 0.05). After the therapy, esophageal cancer, colorectal cancer and gastric cancer patients’ QOL scores, KPS scores were improved, the PS scores were decreased, and the differences were statistically significant (P< 0.05).22 of the patients’recent effects showed that ORR was 9.1%, DCR was 62.8%. The patients’incidence of adverse reactions was 4.26%.Conclusion:1. DC, CIK and CD3AK cells immunotherapy can improve the patients with stage Ⅲ-Ⅳ digestive tract tumor recent immune function; 2 DC, CIK and CD3 AK cells immunotherapy can reduce the level of some tumor markers, the lesions have certain control effect; 3 DC, CIK and CD3AK cells immunotherapy low incidence of adverse reactions, and can improve stage Ⅲ-Ⅳ digestive tract tumors’ quality of life.